<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <fn-group>
  <fn id="jcph1673-note-0001">
   <p>Chandrahas Sahajwalla is a Fellow of the American College of Clinical Pharmacology</p>
  </fn>
  <fn id="jcph1673-note-0002">
   <p>Vikram Arya is a Fellow of the American College of Clinical Pharmacology</p>
  </fn>
  <fn id="jcph1673-note-0003">
   <p>Disclaimer: The views expressed are those of the authors and do not necessarily represent the views of the US FDA or the US Government. The COVID‚Äê19 publications are evolving at a rapid pace and this manuscript is based on papers available at the time of submission to the journal. Therefore, readers are advised to monitor the literature for the most current findings.</p>
  </fn>
  <fn id="jcph1673-note-0032">
   <p>This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as 
    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jcph.1673" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1002/jcph.1673</ext-link>
   </p>
  </fn>
 </fn-group>
</notes>
